Circulating Noncoding RNA Biomarkers for ASD Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Autism Spectrum Disorder (ASD) are subjective and clinical, leading to late or missed diagnoses and ineffective therapeutic interventions, with a lack of objective and systematic methods for identifying children with ASD.
Innovation Solution
The use of differential expression profiles of noncoding RNA molecules, specifically microRNA (miRNA), piwi-interacting RNA (piRNA), small nucleolar RNA (snoRNA), and Y-RNA, measured in blood circulation, to differentiate between severe and mild ASD cases, enabling objective diagnosis and stratification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If subjective and clinical diagnosis methods are used to identify children with ASD, then the diagnosis process is simple and accessible, but the diagnosis accuracy is low and leads to late or missed diagnoses
Solution Approach 1:
The patent replaces subjective clinical diagnosis methods with an objective molecular biology-based detection system. This involves substituting human clinical assessment with automated qRT-PCR technology that measures circulating noncoding RNA levels, thereby eliminating subjectivity and improving diagnostic precision while maintaining operational feasibility through standardized laboratory protocols
Solution Approach 2:
The patent introduces circulating noncoding RNA molecules as intermediary biomarkers that mediate between the disease state and the detection method. These RNA molecules serve as objective indicators that can be quantified to reflect ASD severity, bridging the gap between complex neurological conditions and measurable diagnostic parameters
2Reliability
If circulating noncoding RNA expression profiles are measured to enable objective diagnosis, then diagnosis accuracy improves, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent segments the complex diagnostic problem into manageable components by focusing on specific classes of noncoding RNAs (microRNAs, piRNAs, snoRNAs, Y-RNAs) and further on individual biomarkers within these classes. This segmentation allows the development of targeted assays using qRT-PCR for specific RNA molecules, making the overall diagnostic system more tractable and implementable
Solution Approach 2:
The patent changes the diagnostic parameter from behavioral observations to molecular expression levels. By measuring the expression levels of circulating noncoding RNAs through qRT-PCR, the system transforms an inherently subjective diagnostic process into an objective quantitative measurement, thereby improving reliability while using established molecular biology techniques
Data Source
AI summary
The present specification provides assays for diagnosing and stratifying Autism Spectrum Disorder based on profiles of circulating noncoding RNAs.